AbbVie, Elahere

AbbVie’s Elahere wins European approval for certain ovarian cancers
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab ...
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatments.
AbbVie receives EC approval of Elahere
AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that closed in February.
AbbVie's Elahere Approved in Europe for FRα-Positive Ovarian Cancer
NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate receptor-alpha (FRα)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive,
pharmaphorum6h
AbbVie bags EU nod for key drug from ImmunoGen takeover
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)
Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
Hosted on MSN1mon
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
If approved, this will be the first regulatory approval for Elahere in the EU. ABBV Stock Performance Year to date, AbbVie’s shares have moved up 24.9% compared with the industry’s 23.5% rise.
The Globe and Mail6d
Is This Dividend King a Buy After a Strong Q3 Report?
In the first quarter, AbbVie acquired ImmunoGen and its flagship cancer therapy, ELAHERE. This acquisition will allow ...